1. Home
  2. CTRA vs GMAB Comparison

CTRA vs GMAB Comparison

Compare CTRA & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTRA
  • GMAB
  • Stock Information
  • Founded
  • CTRA 1989
  • GMAB 1999
  • Country
  • CTRA United States
  • GMAB Denmark
  • Employees
  • CTRA N/A
  • GMAB N/A
  • Industry
  • CTRA Oil & Gas Production
  • GMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTRA Energy
  • GMAB Health Care
  • Exchange
  • CTRA Nasdaq
  • GMAB Nasdaq
  • Market Cap
  • CTRA 18.1B
  • GMAB 15.0B
  • IPO Year
  • CTRA 1990
  • GMAB N/A
  • Fundamental
  • Price
  • CTRA $29.47
  • GMAB $20.80
  • Analyst Decision
  • CTRA Strong Buy
  • GMAB Buy
  • Analyst Count
  • CTRA 17
  • GMAB 8
  • Target Price
  • CTRA $32.63
  • GMAB $43.00
  • AVG Volume (30 Days)
  • CTRA 7.1M
  • GMAB 1.1M
  • Earning Date
  • CTRA 02-20-2025
  • GMAB 02-12-2025
  • Dividend Yield
  • CTRA 2.85%
  • GMAB N/A
  • EPS Growth
  • CTRA N/A
  • GMAB 14.35
  • EPS
  • CTRA 1.65
  • GMAB 10.80
  • Revenue
  • CTRA $5,499,000,000.00
  • GMAB $2,967,926,227.00
  • Revenue This Year
  • CTRA N/A
  • GMAB $32.03
  • Revenue Next Year
  • CTRA $35.68
  • GMAB $16.97
  • P/E Ratio
  • CTRA $17.85
  • GMAB $18.81
  • Revenue Growth
  • CTRA N/A
  • GMAB 17.75
  • 52 Week Low
  • CTRA $22.30
  • GMAB $19.85
  • 52 Week High
  • CTRA $29.95
  • GMAB $31.88
  • Technical
  • Relative Strength Index (RSI)
  • CTRA 77.00
  • GMAB 45.42
  • Support Level
  • CTRA $26.09
  • GMAB $19.89
  • Resistance Level
  • CTRA $26.87
  • GMAB $21.26
  • Average True Range (ATR)
  • CTRA 0.61
  • GMAB 0.40
  • MACD
  • CTRA 0.43
  • GMAB -0.02
  • Stochastic Oscillator
  • CTRA 91.22
  • GMAB 38.16

About CTRA Coterra Energy Inc.

Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and NGLs. The company's operations are primarily concentrated in three core operating areas; the Permian Basin in west Texas and southeast New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin in the Mid-Continent region in Oklahoma.

About GMAB Genmab A/S ADS

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: